Jerry Froelich
Overview
Explore the profile of Jerry Froelich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brooks J, Zuro D, Song J, Madabushi S, Sanchez J, Guha C, et al.
Int J Radiat Oncol Biol Phys
. 2021 Nov;
112(4):951-963.
PMID: 34767936
Purpose: Recent initial findings suggest that radiation therapy improves blood perfusion and cellular chemotherapy uptake in mice with leukemia. However, the ability of radiation therapy to influence drug accumulation in...
2.
Zuro D, Madabushi S, Brooks J, Chen B, Goud J, Salhotra A, et al.
Int J Radiat Oncol Biol Phys
. 2021 Jun;
111(3):671-683.
PMID: 34119592
Purpose: Total marrow irradiation (TMI) has significantly advanced radiation conditioning for hematopoietic cell transplantation in hematologic malignancies by reducing conditioning-induced toxicities and improving survival outcomes in relapsed/refractory patients. However, the...
3.
Brooks J, Kumar B, Zuro D, Raybuck J, Madabushi S, Vishwasrao P, et al.
Int J Radiat Oncol Biol Phys
. 2020 Aug;
109(1):60-72.
PMID: 32841681
Purpose: Although vascular alterations in solid tumor malignancies are known to decrease therapeutic delivery, the effects of leukemia-induced bone marrow vasculature (BMV) alterations on therapeutic delivery are not well known....
4.
Nouizi F, Brooks J, Zuro D, Madabushi S, Moreira D, Kortylewski M, et al.
IEEE Access
. 2020 Jun;
8:93663-93670.
PMID: 32542176
Hypofractionated stereotactic body radiotherapy treatments (SBRT) have demonstrated impressive results for the treatment of a variety of solid tumors. The role of tumor supporting vasculature damage in treatment outcome for...
5.
Madan R, Mettler T, Froelich J, Chow L
Am J Case Rep
. 2020 Jun;
21:e923356.
PMID: 32535614
BACKGROUND Hypoglycemia is rare in individuals without drug-treated diabetes mellitus. In a seemingly well individual, the differential diagnosis of hypoglycemia narrows to 2 major categories: 1) accidental, surreptitious, or intentional...
6.
Hoff M, McKinney 4th A, Shellock F, Rassner U, Gilk T, Watson Jr R, et al.
Radiology
. 2019 Jul;
292(3):509-518.
PMID: 31310177
Although 7-T MRI has recently received approval for use in clinical patient care, there are distinct safety issues associated with this relatively high magnetic field. Forces on metallic implants and...
7.
Soubra A, Gencturk M, Froelich J, Balaji P, Gupta S, Jha G, et al.
Clin Genitourin Cancer
. 2018 Jul;
16(5):360-364.
PMID: 30001845
Purpose: To determine the accuracy of F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET/CT) scans in assessing the response to neoadjuvant chemotherapy (NAC) in patients with bladder cancer scheduled...
8.
Magome T, Froelich J, Holtan S, Takahashi Y, Verneris M, Brown K, et al.
Mol Imaging
. 2017 Sep;
16:1536012117732203.
PMID: 28948859
This report describes a multimodal whole-body 3'-deoxy-3'[(18)F]-fluorothymidine positron emission tomography (FLT-PET) and dual-energy computed tomography (DECT) method to identify leukemia distribution within the bone marrow environment (BME) and to develop...
9.
Borgatti A, Winter A, Stuebner K, Scott R, Ober C, Anderson K, et al.
PLoS One
. 2017 Feb;
12(2):e0172651.
PMID: 28222142
Positron Emission Tomography-Computed Tomography (PET-CT) is routinely used for staging and monitoring of human cancer patients and is becoming increasingly available in veterinary medicine. In this study, 18-fluorodeoxyglucose (18FDG)-PET-CT was...
10.
Borgatti A, Koopmeiners J, Sarver A, Winter A, Stuebner K, Todhunter D, et al.
Mol Cancer Ther
. 2017 Feb;
16(5):956-965.
PMID: 28193671
Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that...